{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:51:54Z","timestamp":1791363114013,"version":"4.3.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Project and a Lab Project at Chongqing Three Gorges Medical College","award":["SYS20210021"],"award-info":[{"award-number":["SYS20210021"]}]},{"name":"Chongqing Education Commission Science and Technology Research Program","award":["KJQN202302715"],"award-info":[{"award-number":["KJQN202302715"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00856-9","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T10:15:44Z","timestamp":1738232144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Drug-related macular edema: a real-world FDA Adverse Event Reporting System database study"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-qing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong-lian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Qiang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Feng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhan-Yang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"856_CR1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/ICU.0000000000000714","volume":"31","author":"MJ Khan","year":"2020","unstructured":"Khan MJ, Papakostas T, Kovacs K, Gupta MP. Drug-induced maculopathy. Curr Opin Ophthalmol. 2020;31:563\u201371. https:\/\/doi.org\/10.1097\/ICU.0000000000000714.","journal-title":"Curr Opin Ophthalmol"},{"key":"856_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/978-3-319-95046-4_48","volume":"1085","author":"SH Tsang","year":"2018","unstructured":"Tsang SH, Sharma T. Drug-Induced Retinal toxicity. Adv Exp Med Biol. 2018;1085:227\u201332. https:\/\/doi.org\/10.1007\/978-3-319-95046-4_48.","journal-title":"Adv Exp Med Biol"},{"key":"856_CR3","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40265-013-0055-x","volume":"73","author":"OE Makri","year":"2013","unstructured":"Makri OE, Georgalas I, Georgakopoulos CD. Drug-induced macular edema. Drugs. 2013;73:789\u2013802. https:\/\/doi.org\/10.1007\/s40265-013-0055-x.","journal-title":"Drugs"},{"key":"856_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5694\/mja16.00563","volume":"206","author":"JY Tong","year":"2017","unstructured":"Tong JY, Pai A, Heydon P, Young SH. Clozapine-induced maculopathy. Med J Aust. 2017;206:246. https:\/\/doi.org\/10.5694\/mja16.00563.","journal-title":"Med J Aust"},{"key":"856_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","volume":"9","author":"RJ Yu","year":"2021","unstructured":"Yu RJ, Krantz MS, Phillips EJ, Stone CA. Emerging causes of Drug-Induced anaphylaxis: a review of Anaphylaxis-Associated reports in the FDA adverse event reporting System (FAERS). J Allergy Clin Immunol Pract. 2021;9:819\u2013e8292. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.021.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"856_CR6","doi-asserted-by":"publisher","first-page":"1101861","DOI":"10.3389\/fphar.2023.1101861","volume":"14","author":"Z Fang","year":"2023","unstructured":"Fang Z, Xu Z, Zhu W, et al. A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system. Front Pharmacol. 2023;14:1101861. https:\/\/doi.org\/10.3389\/fphar.2023.1101861.","journal-title":"Front Pharmacol"},{"key":"856_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519\u201323. https:\/\/doi.org\/10.1002\/pds.1001.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"856_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10:483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"856_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00002018-200730070-00011","volume":"30","author":"A Bate","year":"2007","unstructured":"Bate A. Bayesian confidence propagation neural network. Drug Saf. 2007;30:623\u20135. https:\/\/doi.org\/10.2165\/00002018-200730070-00011.","journal-title":"Drug Saf"},{"key":"856_CR10","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1002\/sim.8745","volume":"39","author":"S-J Heo","year":"2020","unstructured":"Heo S-J, Jung I. Extended multi-item gamma Poisson shrinker methods based on the zero-inflated Poisson model for postmarket drug safety surveillance. Stat Med. 2020;39:4636\u201350. https:\/\/doi.org\/10.1002\/sim.8745.","journal-title":"Stat Med"},{"key":"856_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00417-015-3000-8","volume":"254","author":"EJ Sigler","year":"2016","unstructured":"Sigler EJ, Randolph JC, Kiernan DF. Longitudinal analysis of the structural pattern of pseudophakic cystoid macular edema using multimodal imaging. Graefes Arch Clin Exp Ophthalmol. 2016;254:43\u201351. https:\/\/doi.org\/10.1007\/s00417-015-3000-8.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"856_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajo.2017.05.001","volume":"179","author":"KM Lee","year":"2017","unstructured":"Lee KM, Lee EJ, Kim T-W, Kim H. Pseudophakic Macular Edema in Primary Open-Angle Glaucoma: a prospective study using spectral-domain Optical Coherence Tomography. Am J Ophthalmol. 2017;179:97\u2013109. https:\/\/doi.org\/10.1016\/j.ajo.2017.05.001.","journal-title":"Am J Ophthalmol"},{"key":"856_CR13","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/s0886-3350(02)01334-2","volume":"28","author":"PC Yeh","year":"2002","unstructured":"Yeh PC, Ramanathan S. Latanoprost and clinically significant cystoid macular edema after uneventful phacoemulsification with intraocular lens implantation. J Cataract Refract Surg. 2002;28:1814\u20138. https:\/\/doi.org\/10.1016\/s0886-3350(02)01334-2.","journal-title":"J Cataract Refract Surg"},{"key":"856_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/IJG.0b013e3181a98b97","volume":"19","author":"SK Law","year":"2010","unstructured":"Law SK, Kim E, Yu F, Caprioli J. Clinical cystoid macular edema after cataract surgery in glaucoma patients. J Glaucoma. 2010;19:100\u20134.","journal-title":"J Glaucoma"},{"key":"856_CR15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ophtha.2015.10.001","volume":"123","author":"CJ Chu","year":"2016","unstructured":"Chu CJ, Johnston RL, Buscombe C, et al. Risk factors and incidence of Macular Edema after cataract surgery: a database study of 81984 eyes. Ophthalmology. 2016;123:316\u201323. https:\/\/doi.org\/10.1016\/j.ophtha.2015.10.001.","journal-title":"Ophthalmology"},{"key":"856_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1001\/archopht.117.1.34","volume":"117","author":"K Miyake","year":"1999","unstructured":"Miyake K, Ota I, Maekubo K, et al. Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias. Arch Ophthalmol. 1999;117:34\u201340. https:\/\/doi.org\/10.1001\/archopht.117.1.34.","journal-title":"Arch Ophthalmol"},{"key":"856_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1159\/000477897","volume":"10","author":"T Yokoe","year":"2017","unstructured":"Yokoe T, Fukada I, Kobayashi K, et al. Cystoid Macular Edema during treatment with Paclitaxel and Bevacizumab in a patient with metastatic breast Cancer: a Case Report and Literature Review. Case Rep Oncol. 2017;10:605\u201312. https:\/\/doi.org\/10.1159\/000477897.","journal-title":"Case Rep Oncol"},{"key":"856_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2174\/1574886313666180828163016","volume":"14","author":"M Kanakis","year":"2019","unstructured":"Kanakis M, Georgalas I, Makatsoris T, Pharmakakis N. Taxane Induced Cystoid Macular Edema: Case Report and Integrated Pathogenic Theory. Curr Drug Saf. 2019;14:43\u20137. https:\/\/doi.org\/10.2174\/1574886313666180828163016.","journal-title":"Curr Drug Saf"},{"key":"856_CR19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamaophthalmol.2022.3026","volume":"140","author":"M Sodhi","year":"2022","unstructured":"Sodhi M, Yeung SN, Maberley D, et al. Risk of ocular adverse events with taxane-based chemotherapy. JAMA Ophthalmol. 2022;140:880\u20134. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.3026.","journal-title":"JAMA Ophthalmol"},{"key":"856_CR20","doi-asserted-by":"publisher","first-page":"e684","DOI":"10.1200\/JCO.2010.30.3750","volume":"28","author":"CG Murphy","year":"2010","unstructured":"Murphy CG, Walsh JB, Hudis CA, et al. Cystoid macular edema secondary to nab-paclitaxel therapy. J Clin Oncol. 2010;28:e684\u2013687. https:\/\/doi.org\/10.1200\/JCO.2010.30.3750.","journal-title":"J Clin Oncol"},{"key":"856_CR21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3892\/mco.2017.1296","volume":"7","author":"E Bassi","year":"2017","unstructured":"Bassi E, Loizzi V, Furino C, et al. Cystoid macular edema secondary to paclitaxel therapy for ovarian cancer: a case report. Mol Clin Oncol. 2017;7:285\u20137. https:\/\/doi.org\/10.3892\/mco.2017.1296.","journal-title":"Mol Clin Oncol"},{"key":"856_CR22","doi-asserted-by":"publisher","first-page":"e649","DOI":"10.1111\/aos.13219","volume":"96","author":"S-Y Chang","year":"2018","unstructured":"Chang S-Y, Tsai SH, Chen L-J, Chan W-C. Paclitaxel-induced cystoid macular oedema. Acta Ophthalmol. 2018;96:e649\u201350. https:\/\/doi.org\/10.1111\/aos.13219.","journal-title":"Acta Ophthalmol"},{"key":"856_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Andr\u00e9 T, Atreya CE, et al. Combined BRAF, EGFR, and MEK Inhibition in patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov. 2018;8:428\u201343. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1226.","journal-title":"Cancer Discov"},{"key":"856_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus Binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:603\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(18)30142-6.","journal-title":"Lancet Oncol"},{"key":"856_CR25","doi-asserted-by":"publisher","first-page":"vdaa024","DOI":"10.1093\/noajnl\/vdaa024","volume":"2","author":"RD Mazor","year":"2020","unstructured":"Mazor RD, Weissman R, Luckman J, et al. Dual BRAF\/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy. Neurooncol Adv. 2020;2:vdaa024. https:\/\/doi.org\/10.1093\/noajnl\/vdaa024.","journal-title":"Neurooncol Adv"},{"key":"856_CR26","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","volume":"27","author":"PA Ascierto","year":"2021","unstructured":"Ascierto PA, Dr\u00e9no B, Larkin J, et al. 5-Year outcomes with Cobimetinib plus Vemurafenib in BRAFV600 mutation-positive Advanced Melanoma: Extended follow-up of the coBRIM study. Clin Cancer Res. 2021;27:5225\u201335. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0809.","journal-title":"Clin Cancer Res"},{"key":"856_CR27","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12886-018-0861-8","volume":"18","author":"P Tyagi","year":"2018","unstructured":"Tyagi P, Santiago C. New features in MEK retinopathy. BMC Ophthalmol. 2018;18:221. https:\/\/doi.org\/10.1186\/s12886-018-0861-8.","journal-title":"BMC Ophthalmol"},{"key":"856_CR28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1634\/theoncologist.2018-0296","volume":"24","author":"A Chalmers","year":"2019","unstructured":"Chalmers A, Cannon L, Akerley W. Adverse event management in patients with BRAF V600E-Mutant Non-small Cell Lung Cancer treated with Dabrafenib plus Trametinib. Oncologist. 2019;24:963\u201372. https:\/\/doi.org\/10.1634\/theoncologist.2018-0296.","journal-title":"Oncologist"},{"key":"856_CR29","doi-asserted-by":"publisher","first-page":"e000491","DOI":"10.1136\/esmoopen-2019-000491","volume":"4","author":"L Heinzerling","year":"2019","unstructured":"Heinzerling L, Eigentler TK, Fluck M, et al. Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019;4:e000491. https:\/\/doi.org\/10.1136\/esmoopen-2019-000491.","journal-title":"ESMO Open"},{"key":"856_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","volume":"126","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Dummer R, Gogas HJ, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020;126:33\u201344. https:\/\/doi.org\/10.1016\/j.ejca.2019.11.016.","journal-title":"Eur J Cancer"},{"key":"856_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejca.2016.06.018","volume":"65","author":"U Urner-Bloch","year":"2016","unstructured":"Urner-Bloch U, Urner M, Jaberg-Bentele N, et al. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: long-term ophthalmic effects. Eur J Cancer. 2016;65:130\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.06.018.","journal-title":"Eur J Cancer"},{"key":"856_CR32","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3390\/cancers11111642","volume":"11","author":"O Hamid","year":"2019","unstructured":"Hamid O, Cowey CL, Offner M, et al. Efficacy, Safety, and tolerability of approved combination BRAF and MEK inhibitor regimens for BRAF-Mutant melanoma. Cancers (Basel). 2019;11:1642. https:\/\/doi.org\/10.3390\/cancers11111642.","journal-title":"Cancers (Basel)"},{"key":"856_CR33","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/IAE.0000000000002451","volume":"39","author":"S M\u00e9ndez-Mart\u00ednez","year":"2019","unstructured":"M\u00e9ndez-Mart\u00ednez S, Calvo P, Ruiz-Moreno O, et al. OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS. Retina. 2019;39:1435\u201350. https:\/\/doi.org\/10.1097\/IAE.0000000000002451.","journal-title":"Retina"},{"key":"856_CR34","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13643-021-01782-7","volume":"10","author":"J Mu\u00f1oz-Ortiz","year":"2021","unstructured":"Mu\u00f1oz-Ortiz J, Reyes-Guanes J, Zapata-Bravo E, et al. Ocular adverse events from pharmacological treatment in patients with multiple sclerosis-A systematic review of the literature. Syst Rev. 2021;10:280. https:\/\/doi.org\/10.1186\/s13643-021-01782-7.","journal-title":"Syst Rev"},{"key":"856_CR35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.nrl.2016.08.005","volume":"34","author":"P Cifuentes-Canorea","year":"2019","unstructured":"Cifuentes-Canorea P, Nieves-Moreno M, S\u00e1enz-Franc\u00e9s F, Santos-Bueso E. Early and recurrent macular oedema in a patient treated with fingolimod. Neurologia (Engl Ed). 2019;34:206\u20137. https:\/\/doi.org\/10.1016\/j.nrl.2016.08.005.","journal-title":"Neurologia (Engl Ed)"},{"key":"856_CR36","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391:1263\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(18)30475-6.","journal-title":"Lancet"},{"key":"856_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/DHPS.S69640","volume":"7","author":"A Gajofatto","year":"2015","unstructured":"Gajofatto A, Turatti M, Monaco S, Benedetti MD. Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drug Healthc Patient Saf. 2015;7:157\u201367. https:\/\/doi.org\/10.2147\/DHPS.S69640.","journal-title":"Drug Healthc Patient Saf"},{"key":"856_CR38","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1001\/jamaophthalmol.2015.2421","volume":"133","author":"DC Wong","year":"2015","unstructured":"Wong DC, Waxman MD, Herrinton LJ, Shorstein NH. Transient macular edema after intracameral injection of a moderately elevated dose of cefuroxime during phacoemulsification surgery. JAMA Ophthalmol. 2015;133:1194\u20137. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.2421.","journal-title":"JAMA Ophthalmol"},{"key":"856_CR39","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.jcrs.2010.07.007","volume":"36","author":"HZ Buyukyildiz","year":"2010","unstructured":"Buyukyildiz HZ, Gulkilik G, Kumcuoglu YZ. Early serous macular detachment after phacoemulsification surgery. J Cataract Refract Surg. 2010;36:1999\u20132002. https:\/\/doi.org\/10.1016\/j.jcrs.2010.07.007.","journal-title":"J Cataract Refract Surg"},{"key":"856_CR40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3109\/15569527.2013.835817","volume":"33","author":"A Kontos","year":"2014","unstructured":"Kontos A, Mitry D, Althauser S, Jain S. Acute serous macular detachment and cystoid macular edema after uncomplicated phacoemulsification using standard dose subconjunctival cefuroxime. Cutan Ocul Toxicol. 2014;33:233\u20134. https:\/\/doi.org\/10.3109\/15569527.2013.835817.","journal-title":"Cutan Ocul Toxicol"},{"key":"856_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10633-014-9465-7","volume":"130","author":"C Faure","year":"2015","unstructured":"Faure C, Perreira D, Audo I. Retinal toxicity after intracameral use of a standard dose of cefuroxime during cataract surgery. Doc Ophthalmol. 2015;130:57\u201363. https:\/\/doi.org\/10.1007\/s10633-014-9465-7.","journal-title":"Doc Ophthalmol"},{"key":"856_CR42","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1016\/j.jcjo.2016.05.008","volume":"51","author":"M Aslankurt","year":"2016","unstructured":"Aslankurt M, \u00c7eki\u00e7 O, And\u0131 \u0130, Dursun O. Transient macular edema after standard dose of intracameral cefuroxime injection during phacoemulsification. Can J Ophthalmol. 2016;51:e141\u20132. https:\/\/doi.org\/10.1016\/j.jcjo.2016.05.008.","journal-title":"Can J Ophthalmol"},{"key":"856_CR43","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1001\/jamaophthalmol.2016.1351","volume":"134","author":"V Daien","year":"2016","unstructured":"Daien V, Papinaud L, Gillies MC, et al. Effectiveness and safety of an Intracameral injection of Cefuroxime for the Prevention of endophthalmitis after cataract surgery with or without Perioperative Capsular rupture. JAMA Ophthalmol. 2016;134:810\u20136. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.1351.","journal-title":"JAMA Ophthalmol"},{"key":"856_CR44","doi-asserted-by":"publisher","first-page":"101228","DOI":"10.1016\/j.ajoc.2021.101228","volume":"24","author":"J Regenold","year":"2021","unstructured":"Regenold J, Ghoraba H, Akhavanrezayat A, et al. Unilateral acute anterior uveitis with macular edema following the use of sildenafil citrate in a patient with HLA-B27 positivity. Am J Ophthalmol Case Rep. 2021;24:101228. https:\/\/doi.org\/10.1016\/j.ajoc.2021.101228.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"856_CR45","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40942-020-00241-0","volume":"6","author":"NFS da Cruz","year":"2020","unstructured":"da Cruz NFS, Polizelli MU, Cezar LM, et al. Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review. Int J Retina Vitreous. 2020;6:38. https:\/\/doi.org\/10.1186\/s40942-020-00241-0.","journal-title":"Int J Retina Vitreous"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00856-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00856-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00856-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T10:15:52Z","timestamp":1738232152000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00856-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["856"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00856-9","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"16 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Considering that the FAERS database is publicly accessible, and patient records are anonymous and de-identified, it does not involve informed consent or ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations and informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}